Pα is the insider’s guide to the business, policy and science of psychedelics. Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. psychedelicalpha.com/join

Real-World Psilocybin for TRD Data from Zurich Read more on our website: psychedelicalpha.com/news/p%…

American Psychiatrists’ Psychedelics Word Associations An informal poll conducted at a psychedelics-focused session at the American Psychiatric Association’s annual meeting last month revealed common word associations that psychiatrists in attendance have with the term “psychedelic”. Read more on our website: psychedelicalpha.com/news/a-…

Q1 2026 Federal Psychedelic Lobbying Update Now that federal lobbying data from the first quarter of the year is available to retrieve, we present our regular update on the state of activity across psychedelic drug developers and nonprofits. Read more on our website: psychedelicalpha.com/news/p%…

May 2026 Psychedelic Bill Round-up Read more on our website: psychedelicalpha.com/news/ma…

Ten Psychedelics-Related Questions on American Psychiatrists’ Minds Read more on our website: psychedelicalpha.com/news/a-…

Field Notes #2: Dispatches from London and the Netherlands Listen now on our website: psychedelicalpha.com/news/fi…

We just returned from the OPEN Foundation's Interdisciplinary Conference on Psychedelic Research (ICPR) in Haarlem, the Netherlands. Psychedelic Alpha Founder and Editor Josh Hardman gave a presentation on the state of psychedelic drug development and related open questions and participated in the Closing Panel on Saturday evening.

State of Maryland and Reason for Hope Fund Sunstone Study to Compare Group vs. Individual MDMA-Assisted Therapy for PTSD Read more on our website: psychedelicalpha.com/news/p%…

New Poll Finds Brits Generally Supportive of Psilocybin Access A new YouGov poll commissioned by UK advocacy group Psilocybin Access Rights (PAR) reports that 68% of British adults are in favour of allowing terminally ill people access to psilocybin-based treatments for end-of-life psychological distress, with just 8% opposed. Support was seen across all five major political parties in the country. When it comes to medical access for mental health conditions, support was less overwhelming. Still, a majority (53) support it, with just 18% opposed. Just over a quarter (28%) said they did not know. Read more on our website: psychedelicalpha.com/news/p%…

“I went to Transcend because I was concerned, actually, about pretty severe QT prolongation with ibogaine. I wanted to understand how they were doing it, because I was afraid that they’re going to have very serious cardiac arrhythmias” Nora Volkow shared her views on psychedelics via a presentation at the American Psychiatric Association's annual meeting in San Francisco. Read the full interview and transcript, and access Volkow's slides, at our website: psychedelicalpha.com/news/if…

Informal Poll of American Psychiatrists Suggests Hesitancy Around Psychedelics An informal poll conducted at a psychedelics-focused session at the American Psychiatric Association’s annual meeting last month found that psychiatrists in attendance were not likely to consider recommending psychedelic treatment to patients at present. That is perhaps unsurprising, given the fact that no psychedelic has received FDA approval at present. Read more on our website: psychedelicalpha.com/news/a-…

“If humans have recognised their value in ceremonial and spiritual contexts for millennia, it suggests these substances do something profoundly meaningful. Religion and ceremony have always been central to civilisation, so the enduring presence of psychedelics in those settings tells us something important.” Nora Volkow shared her views on psychedelics via a presentation at the American Psychiatric Association's annual meeting in San Francisco. Read the full interview and transcript, and access Volkow's slides, at our website: psychedelicalpha.com/news/if…

A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry Last month, our Editor, Josh Hardman, attended the American Psychiatric Association’s (APA) five-day annual meeting in San Francisco. There, he took the temperature of a field that is struggling to make sense of its standing in American society, and that is now confronted with a class of potential therapeutics—psychedelics—that it can’t quite place. Over the course of the meeting, Hardman spoke with psychiatrists of all stripes, from interventional specialists working at the field’s cutting edge through to the rank-and-file and outright skeptics of modalities like TMS, ketamine, and psychedelics.  In our latest, we share our key takeaways: a temperature check on psychiatrists’ views on the class, the questions most on their minds when it comes to psychedelics, and a closer look at the meeting’s psychedelics-focused programming. Read now: psychedelicalpha.com/news/p%…

“...once the drug leaves the bloodstream and the brain, therapeutic benefits persist after a single administration. That’s extraordinary. In psychiatry, few interventions produce immediate and lasting effects.” Nora Volkow shared her views on psychedelics via a presentation at the American Psychiatric Association's annual meeting in San Francisco. Read the full interview and transcript, and access Volkow's slides, at our website: psychedelicalpha.com/news/if…

Explore Our Updated Psychedelics Job Board & Talent Network Whether you’re looking to break into the psychedelics field, take the next step in your career, or connect with talent, Psychedelic Alpha’s Job Board & Talent Network is built to help you navigate the opportunities shaping the sector. The board features roles across psychedelic biotech, research, policy, care delivery, clinics, legal and regulatory, marketing, finance, and more. Explore the board here: jobs.psychedelicalpha.com/

“We found that participants who were the most pessimistic and hopeless at baseline tended to preserve that negativity on the post-dosing day and remained as non-responders.” - Scott T. Aaronson Read the full conversation on our website: psychedelicalpha.com/news/ps…

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval In our first Field Note, Psychedelic Alpha Founder & Editor Josh Hardman discusses the American Psychiatric Association’s annual meeting, ibogaine drug development post-EO, FDA-related developments, and the race to approval for two psilocybin drug developers: Compass Pathways and Usona Institute. Listen on our website: psychedelicalpha.com/news/fi…

“Of course, expectations and placebo effects can be powerful, and we must question them. Yet if a placebo produced a 90% increase in life satisfaction, I’d want to know what makes that placebo so impactful!” Nora Volkow shared her views on psychedelics via a presentation at the American Psychiatric Association's annual meeting in San Francisco. Read the full interview and transcript, and access Volkow's slides, at our website: psychedelicalpha.com/news/if…

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race Last week, I (the Editor, Josh Hardman) returned from a trip to the U.S. West Coast, visiting San Francisco for the American Psychiatric Association’s annual meeting and Palo Alto, where I caught up with researchers, investors, and others close to the psychedelics field. While I was there, the Food and Drug Administration (FDA) generated several headlines, including the resignation of Commissioner Marty Makary and the ouster of Tracy Beth Høeg, the acting director of the Center for Drug Evaluation and Research; both darlings of the MAHA movement, at least initially. Ex-Usona Institute Chief Medical Officer Mike Davis has since filled the latter’s shoes. Here, I share what the FDA reshuffle might mean for psychedelics, as well as recent comments from the agency’s Division of Psychiatry director Tiffany Farchione, a closer look at potential approval timelines, and a deep dive into the race to market for two psilocybin developers, Compass Pathways and Usona, which now appears too close to call. Read more on our website: psychedelicalpha.com/news/mo…

New: Pa Field Notes Timely, candid voice notes from our Founder & Editor, Josh Hardman, covering recent developments in psychedelic drug development, policy, and access in under fifteen minutes. Listen on our website: psychedelicalpha.com/news/fi…